<DOC>
	<DOC>NCT02520102</DOC>
	<brief_summary>Primary Objective: Measure the proportion of patients who develop binding and neutralizing antibodies in the blood after treatment with sargramostim following induction/reinduction chemotherapy. Secondary Objectives: - Assess the time after treatment at which the antibodies develop and the level of antibodies is measured after the first dose. - Measure the levels of immunoglobulin protein. - Assess the impact of any immune response on safety and the duration of low white blood cell count.</brief_summary>
	<brief_title>Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia</brief_title>
	<detailed_description>The total study duration for a participant is up to 6 months from 1st dose of sargramostim or until the antibodies level return to baseline or up to 24 months if antibodies test is positive at month 6.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<criteria>Inclusion criteria : Able to provide informed consent. Newly diagnosed acute myeloid leukemia (AML) to be treated with standard of care induction chemotherapy as per local policy. Patients 55 to 70 years of age (inclusive). Negative serum pregnancy test within 30 days prior to receiving the first dose of induction chemotherapy in female participants who are &lt;2 years postmenopausal or who are of childbearing potential and have agreed to begin or continue using an adequate method of contraception. Exclusion criteria: Prior treatment with sargramostim or any leukocyte growth factor (LGF) product. Prior myelodysplastic syndrome (MDS). Known central nervous system (CNS) leukemic involvement diagnosed by cytologic findings in cerebrospinal fluid and/or by computed tomography (CT) or magnetic resonance imaging (MRI). Out of range (&gt;2x normal) laboratory values. Clinically important medical conditions unrelated to AML as determined by the Investigator. Eastern Cooperative Oncology Group (ECOG) performance status &gt;2. Bone marrow blasts â‰¥5% on marrow examination following induction or reinduction chemotherapy. History of allergy to yeast products, recombinant human granulocyte/macrophagecolonystimulating factor, or any component of sargramostim. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>